{"entity":{"id":"nct07521852","kind":"trial","name":"A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Part","aka":[],"tldr":"A phase 2 trial of Sintilimab in hepatocellular carcinoma, run by TaiRx, Inc., now recruiting.","summary":"A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC is a phase 2 interventional study registered as NCT07521852 by TaiRx, Inc., with 40 participants planned, started 2026-03-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: CVM-1118 + Sintilimab + TACE. Conditions listed: HCC - Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07521852","url":"https://clinicaltrials.gov/study/NCT07521852"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hcc","hcc-intermediate"],"sections":[],"technologies":["checkpoint-inhibitor","monoclonal-antibody"],"targets":[],"drugs":["sintilimab"],"companies":["tairx"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07521852","phase":"2","setting":"A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetic (PK) of CVM-1118 in Combination With Sintilimab and Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma","sponsor":"TaiRx, Inc.","started":"2026-03-31","startedType":"actual","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07521852/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"hcc-intermediate","kind":"cancer","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/cancers/hcc-intermediate/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"company":[{"id":"tairx","kind":"company","name":"TaiRx","route":"/companies/tairx/"}]}}